Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie k hodnocení dlouhodobé bezpečnosti, snášenlivosti a účinnosti bimekizumabu u pacientů s aktivní axiální spondyloartritidou včetně ankylozující spondylitidy a neradiografické axiální spondyloartritidy (BE MOVING)

2. listopadu 2026 aktualizováno: UCB Biopharma SRL

Multicentrická, otevřená rozšiřující studie k posouzení dlouhodobé bezpečnosti, snášenlivosti a účinnosti bimekizumabu při léčbě účastníků studie s aktivní axiální spondyloartritidou, ankylozující spondylitidou a neradiografickou axiální spondyloartritidou

The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).

Přehled studie

Typ studie

Intervenční

Zápis (Aktuální)

508

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Brussels, Belgie
        • As0014 40004
      • Genk, Belgie
        • As0014 40003
      • Ghent, Belgie
        • As0014 40001
      • Plovdiv, Bulharsko
        • As0014 40006
      • Plovdiv, Bulharsko
        • As0014 40007
      • Sofia, Bulharsko
        • As0014 40005
      • Sofia, Bulharsko
        • As0014 40008
      • Boulogne-Billancourt, Francie
        • As0014 40018
      • Limoges, Francie
        • As0014 40022
      • Amsterdam, Holandsko
        • As0014 40034
      • Bunkyō City, Japonsko
        • As0014 20035
      • Chūōku, Japonsko
        • As0014 20030
      • Iruma-gun, Japonsko
        • As0014 20039
      • Kawachi-Nagano, Japonsko
        • As0014 20036
      • Kita-gun, Japonsko
        • As0014 20045
      • Kitakyushu, Japonsko
        • As0014 20065
      • Osaka, Japonsko
        • As0014 20037
      • Saga, Japonsko
        • As0014 20084
      • Saitama, Japonsko
        • As0014 20048
      • Sapporo, Japonsko
        • As0014 20031
      • Suita, Japonsko
        • As0014 20032
      • Debrecen, Maďarsko
        • As0014 40032
      • Szeged, Maďarsko
        • As0014 40031
      • Székesfehérvár, Maďarsko
        • As0014 40033
      • Berlin, Německo
        • As0014 40025
      • Hamburg, Německo
        • As0014 40029
      • Hanover, Německo
        • As0014 40024
      • Herne, Německo
        • As0014 40027
      • Leipzig, Německo
        • As0014 40078
      • Ratingen, Německo
        • As0014 40026
      • Elblag, Polsko
        • As0014 40038
      • Krakow, Polsko
        • As0014 40042
      • Lublin, Polsko
        • As0014 40037
      • Poznan, Polsko
        • As0014 40044
      • Torun, Polsko
        • As0014 40040
      • Warsaw, Polsko
        • As0014 40041
      • Wroclaw, Polsko
        • As0014 40039
      • Wroclaw, Polsko
        • As0014 40043
      • Edinburgh, Spojené království
        • As0014 40057
      • Leeds, Spojené království
        • As0014 40056
      • Norwich, Spojené království
        • As0014 40055
    • Arizona
      • Glendale, Arizona, Spojené státy, 85306
        • As0014 50062
      • Phoenix, Arizona, Spojené státy, 85032
        • As0014 50052
    • California
      • Upland, California, Spojené státy, 91786
        • As0014 50060
    • Florida
      • Ormond Beach, Florida, Spojené státy, 32174
        • As0014 50059
      • Sarasota, Florida, Spojené státy, 34239
        • As0014 50056
    • Maryland
      • Hagerstown, Maryland, Spojené státy, 21740
        • As0014 50015
    • Missouri
      • St Louis, Missouri, Spojené státy, 63141
        • As0014 50016
    • Oregon
      • Portland, Oregon, Spojené státy, 97239
        • As0014 50055
    • Pennsylvania
      • Duncansville, Pennsylvania, Spojené státy, 16635
        • As0014 50020
    • Texas
      • Dallas, Texas, Spojené státy, 75231
        • As0014 50057
      • Ankara, Turecko (Türkiye)
        • As0014 40052
      • Ankara, Turecko (Türkiye)
        • As0014 40053
      • Istanbul, Turecko (Türkiye)
        • As0014 40050
      • Brno, Česko
        • As0014 40011
      • Pardubice, Česko
        • As0014 40009
      • Prague, Česko
        • As0014 40013
      • Prague, Česko
        • As0014 40014
      • Prague, Česko
        • As0014 40015
      • Prague, Česko
        • As0014 40016
      • Uherské Hradiště, Česko
        • As0014 40010
      • Zlín, Česko
        • As0014 40012
      • Beijing, Čína
        • As0014 20040
      • Chengdu, Čína
        • As0014 20021
      • Guangzhou, Čína
        • As0014 20019
      • Hefei, Čína
        • As0014 20034
      • Nanjing, Čína
        • As0014 20024
      • Shanghai, Čína
        • As0014 20018
      • Shanghai, Čína
        • As0014 20020
      • Shanghai, Čína
        • As0014 20026
      • Wenzhou, Čína
        • As0014 20025
      • A Coruña, Španělsko
        • As0014 40045
      • Córdoba, Španělsko
        • As0014 40046
      • Santiago de Compostela, Španělsko
        • As0014 40048
      • Seville, Španělsko
        • As0014 40049

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Study participant is considered reliable and capable of adhering to the protocol (eg, able to understand and complete questionnaires), visit schedule, and medication intake according to the judgement of the Investigator
  • In the opinion of the Investigator, the study participant is expected to benefit from participation in this extension study
  • Study participant completed AS0010 (NCT03928704) or AS0011 (NCT03928743)

Exclusion Criteria:

  • Female study participants who plan to become pregnant during the study or within 20 weeks following final dose of Investigational Medicinal Product (IMP). Male study participants who are planning a partner pregnancy during the study or within 20 weeks following the final dose
  • Study participants who meet any withdrawal criteria in AS0010 or AS0011. For any study participant with an ongoing serious adverse event (SAE), or a history of serious infections (including hospitalizations) in the feeder study, the Medical Monitor must be consulted prior to the study participant's entry into AS0014
  • Study participant has a positive or indeterminate interferon gamma release assay (IGRA) in AS0010 or AS0011, unless appropriately evaluated and treated

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Bimekizumab

Subjects will receive bimekizumab throughout the Treatment Period.

Subjects will receive bimekizumab at prespecified time-points.

Ostatní jména:
  • UCB4940
  • BKZ

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
Časové okno: From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
Percentage of participants with serious adverse events (SAEs) during the study
Časové okno: From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

A serious adverse event (SAE) is any untoward medical occurrence that at any dose:

  • Results in death
  • Is life-threatening
  • Requires in patient hospitalisation or prolongation of existing hospitalisation
  • Is a congenital anomaly or birth defect
  • Is an infection that requires treatment with parenteral antibiotics
  • Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above
From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
Percentage of participants with with treatment-emergent adverse Events (TEAEs) leading to withdrawal from the study
Časové okno: From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

From Baseline (Day 1) until Safety Follow-Up (up to Week 180)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 28
Časové okno: Week 28

ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))-
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 5 and 6 concerning morning stiffness intensity and duration)
Week 28
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 52
Časové okno: Week 52

ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 52
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 112
Časové okno: Week 112

ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 112
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 28
Časové okno: Week 28

ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 28
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 52
Časové okno: Week 52

ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 52
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 112
Časové okno: Week 112

ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain.

The domains are:

  • Patient's Global Assessment of Disease Activity (PGADA)
  • Pain assessment (the total spinal pain, NRS score)
  • Function (represented by Bath Ankylosing Spondylitis Functional Index (BASFI))
  • Inflammation (the mean of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI))
Week 112
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 28
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 52
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 112
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 28
Časové okno: Week 28

The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS40 domains.

Week 28
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 52
Časové okno: Week 52

The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS domains.

Week 52
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 112
Časové okno: Week 112

The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS domains.

Week 112
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 28
Časové okno: Week 28

The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below:

0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.

Week 28
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 52
Časové okno: Week 52

The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below:

0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.

Week 52
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 112
Časové okno: Week 112

The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below:

0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.+ 1)

Week 112
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 28
Časové okno: Week 28

The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS40 domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

Week 28
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 52
Časové okno: Week 52

The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

Week 52
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 112
Časové okno: Week 112

The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP).

Week 112
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 28
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 52
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 112
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in Nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 28
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 52
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 112
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 28
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 52
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 112
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 28
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 52
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 28
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 52
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the sum of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 112
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the sum of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 28
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28

The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 52
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52

The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 112
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 112
Časové okno: From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement.

From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Ředitel studie: UCB Cares, 001 844 599 2273 (UCB)

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

16. června 2020

Primární dokončení (Aktuální)

9. srpna 2026

Dokončení studie (Aktuální)

9. srpna 2026

Termíny zápisu do studia

První předloženo

15. června 2020

První předloženo, které splnilo kritéria kontroly kvality

15. června 2020

První zveřejněno (Aktuální)

18. června 2020

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

5. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • AS0014
  • 2019-004163-47 (Číslo EudraCT)
  • 2023-506527-28 (Identifikátor registru: EU Clinical Trials)
  • U1111-1304-6865 (Jiný identifikátor: World Health Organization (WHO))
  • 2023 (Grant/smlouva NIH USA)
  • 2019 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Časový rámec sdílení IPD

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Kritéria přístupu pro sdílení IPD

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA
  • CSR

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit